Passage Bio, Inc.

Clinical trials sponsored by Passage Bio, Inc., explained in plain language.

Passage Bio, Inc. PASG NASDAQ

A clinical-stage gene therapy company developing treatments for rare neurological diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

Could a single gene injection slow frontotemporal dementia?

Disease control Ongoing

This early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…

Phase 1/2 • Sponsor: Passage Bio, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:33 UTC

Passage Bio, Inc.

Could a single gene injection slow frontotemporal dementia?